JP2019536473A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019536473A5 JP2019536473A5 JP2019540142A JP2019540142A JP2019536473A5 JP 2019536473 A5 JP2019536473 A5 JP 2019536473A5 JP 2019540142 A JP2019540142 A JP 2019540142A JP 2019540142 A JP2019540142 A JP 2019540142A JP 2019536473 A5 JP2019536473 A5 JP 2019536473A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- human
- hiv
- virus
- expression vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims description 87
- 102000036639 antigens Human genes 0.000 claims description 87
- 108091007433 antigens Proteins 0.000 claims description 87
- 239000013604 expression vector Substances 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 241001115402 Ebolavirus Species 0.000 claims description 8
- 241000701806 Human papillomavirus Species 0.000 claims description 8
- 241000712431 Influenza A virus Species 0.000 claims description 8
- 241000710886 West Nile virus Species 0.000 claims description 8
- 108020001507 fusion proteins Proteins 0.000 claims description 8
- 102000037865 fusion proteins Human genes 0.000 claims description 8
- 229960005486 vaccine Drugs 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 6
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 claims description 5
- 101150029707 ERBB2 gene Proteins 0.000 claims description 5
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims description 5
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 5
- 101150010086 VP24 gene Proteins 0.000 claims description 5
- 101150036892 VP40 gene Proteins 0.000 claims description 5
- 210000004899 c-terminal region Anatomy 0.000 claims description 4
- 230000002163 immunogen Effects 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 230000005867 T cell response Effects 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 108700020134 Human immunodeficiency virus 1 nef Proteins 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 241000725303 Human immunodeficiency virus Species 0.000 claims 6
- 201000001441 melanoma Diseases 0.000 claims 6
- 230000035772 mutation Effects 0.000 claims 4
- 230000036039 immunity Effects 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- 208000035473 Communicable disease Diseases 0.000 description 4
- 210000001808 exosome Anatomy 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 208000000307 Crimean Hemorrhagic Fever Diseases 0.000 description 2
- 201000003075 Crimean-Congo hemorrhagic fever Diseases 0.000 description 2
- 208000030820 Ebola disease Diseases 0.000 description 2
- 108010071463 Melanoma-Specific Antigens Proteins 0.000 description 2
- 102000007557 Melanoma-Specific Antigens Human genes 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 208000037841 lung tumor Diseases 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 208000023958 prostate neoplasm Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022032547A JP7340639B2 (ja) | 2016-10-11 | 2022-03-03 | ワクチンとして使用するためのエキソソームアンカータンパク質を発現するヌクレオチド配列 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102016000101794A IT201600101794A1 (it) | 2016-10-11 | 2016-10-11 | Sequenza nucleotidica esprimente una proteina ancorante esosomi per uso come vaccino. |
| IT102016000101794 | 2016-10-11 | ||
| PCT/IT2017/000223 WO2018069947A1 (en) | 2016-10-11 | 2017-10-11 | Nucleotide sequence expressing an exosome-anchoring protein for use as vaccine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022032547A Division JP7340639B2 (ja) | 2016-10-11 | 2022-03-03 | ワクチンとして使用するためのエキソソームアンカータンパク質を発現するヌクレオチド配列 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019536473A JP2019536473A (ja) | 2019-12-19 |
| JP2019536473A5 true JP2019536473A5 (enExample) | 2021-02-12 |
Family
ID=58609653
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019540142A Pending JP2019536473A (ja) | 2016-10-11 | 2017-10-11 | ワクチンとして使用するためのエキソソームアンカータンパク質を発現するヌクレオチド配列 |
| JP2022032547A Active JP7340639B2 (ja) | 2016-10-11 | 2022-03-03 | ワクチンとして使用するためのエキソソームアンカータンパク質を発現するヌクレオチド配列 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022032547A Active JP7340639B2 (ja) | 2016-10-11 | 2022-03-03 | ワクチンとして使用するためのエキソソームアンカータンパク質を発現するヌクレオチド配列 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11559571B2 (enExample) |
| EP (1) | EP3389701B1 (enExample) |
| JP (2) | JP2019536473A (enExample) |
| KR (1) | KR102620487B1 (enExample) |
| CN (2) | CN110049775A (enExample) |
| AU (1) | AU2017343893B2 (enExample) |
| BR (1) | BR112019007343A2 (enExample) |
| CA (1) | CA3040035A1 (enExample) |
| DK (1) | DK3389701T3 (enExample) |
| ES (1) | ES2809212T3 (enExample) |
| HU (1) | HUE050492T2 (enExample) |
| IL (1) | IL265942B2 (enExample) |
| IT (1) | IT201600101794A1 (enExample) |
| MX (1) | MX2019004183A (enExample) |
| RU (1) | RU2761642C2 (enExample) |
| SG (1) | SG11201903235XA (enExample) |
| WO (1) | WO2018069947A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT201600101794A1 (it) | 2016-10-11 | 2018-04-11 | St Superiore Di Sanita | Sequenza nucleotidica esprimente una proteina ancorante esosomi per uso come vaccino. |
| IT202000009688A1 (it) | 2020-05-04 | 2021-11-04 | Biovelocita S R L | Proteine di fusione di ancoraggio a esosomi |
| WO2021224429A1 (en) | 2020-05-06 | 2021-11-11 | Biovelocita S.R.L | Exosome-anchoring coronavirus fusion proteins and vaccines |
| IT202000030740A1 (it) | 2020-12-14 | 2022-06-14 | St Superiore Di Sanita | SEQUENZA NUCLEOTIDICA ESPRIMENTE UNA PROTEINA ANCORANTE VESCICOLE EXTRACELLULARI FUSA AD ANTIGENI DI SARS-CoV-2 E RELATIVA PROTEINA DI FUSIONE PER L’USO COME VACCINO |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6534285B1 (en) * | 1984-12-24 | 2003-03-18 | Genentech, Inc. | Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use |
| GB0118532D0 (en) | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
| FR2928926B1 (fr) | 2008-03-18 | 2015-08-21 | Centre Nat Rech Scient | Polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leur utilisation pour la production de compositions immunogenes |
| US10238734B2 (en) | 2010-03-23 | 2019-03-26 | The Regents Of The University Of California | Compositions and methods for self-adjuvanting vaccines against microbes and tumors |
| US20130101614A1 (en) | 2010-06-15 | 2013-04-25 | The Regents Of The University Of California | Novel live recombinant booster vaccine against tuberculosis |
| JP2017513860A (ja) | 2014-04-24 | 2017-06-01 | スタテンス セールム インスティトゥート | 新規結核菌（ｍ．ｔｕｂｅｒｃｕｌｏｓｉｓ）ワクチン |
| IT201600101794A1 (it) | 2016-10-11 | 2018-04-11 | St Superiore Di Sanita | Sequenza nucleotidica esprimente una proteina ancorante esosomi per uso come vaccino. |
| IT201600131935A1 (it) | 2016-12-29 | 2018-06-29 | Enea Agenzia Naz Per Le Nuove Tecnologie Lenergia E Lo Sviluppo Economico Sostenibile | Sequenza segnale di proteina vegetale come coadiuvante in vaccini a DNA. |
| US11130787B2 (en) | 2020-06-11 | 2021-09-28 | MBF Therapeutics, Inc. | Alphaherpesvirus glycoprotein d-encoding nucleic acid constructs and methods |
| CN112409496B (zh) | 2020-11-26 | 2021-07-13 | 焦顺昌 | 一种跨膜表达新型冠状病毒抗原s2的融合蛋白、重组载体、重组树突状细胞及其应用 |
-
2016
- 2016-10-11 IT IT102016000101794A patent/IT201600101794A1/it unknown
-
2017
- 2017-10-11 ES ES17826320T patent/ES2809212T3/es active Active
- 2017-10-11 DK DK17826320.8T patent/DK3389701T3/da active
- 2017-10-11 KR KR1020197013580A patent/KR102620487B1/ko active Active
- 2017-10-11 EP EP17826320.8A patent/EP3389701B1/en active Active
- 2017-10-11 CA CA3040035A patent/CA3040035A1/en active Pending
- 2017-10-11 US US16/341,042 patent/US11559571B2/en active Active
- 2017-10-11 CN CN201780076288.2A patent/CN110049775A/zh active Pending
- 2017-10-11 WO PCT/IT2017/000223 patent/WO2018069947A1/en not_active Ceased
- 2017-10-11 HU HUE17826320A patent/HUE050492T2/hu unknown
- 2017-10-11 IL IL265942A patent/IL265942B2/en unknown
- 2017-10-11 SG SG11201903235XA patent/SG11201903235XA/en unknown
- 2017-10-11 RU RU2019114370A patent/RU2761642C2/ru active
- 2017-10-11 JP JP2019540142A patent/JP2019536473A/ja active Pending
- 2017-10-11 CN CN202310836753.5A patent/CN117210480A/zh active Pending
- 2017-10-11 AU AU2017343893A patent/AU2017343893B2/en active Active
- 2017-10-11 BR BR112019007343A patent/BR112019007343A2/pt not_active Application Discontinuation
- 2017-10-11 MX MX2019004183A patent/MX2019004183A/es unknown
-
2022
- 2022-03-03 JP JP2022032547A patent/JP7340639B2/ja active Active
-
2023
- 2023-01-20 US US18/157,534 patent/US20230364211A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tian et al. | Development of therapeutic vaccines for the treatment of diseases | |
| Melief et al. | Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines | |
| JP2019526580A5 (enExample) | ||
| Roose et al. | Hepatitis B core–based virus–like particles to present heterologous epitopes | |
| JP2019536473A5 (enExample) | ||
| JP2009544614A5 (enExample) | ||
| JP2022071130A5 (enExample) | ||
| JP2016516723A5 (enExample) | ||
| JP2016503029A5 (enExample) | ||
| JP2016520530A5 (enExample) | ||
| Al-Barwani et al. | Antigen delivery by virus-like particles for immunotherapeutic vaccination | |
| Cordeiro et al. | Current research into novel therapeutic vaccines against cervical cancer | |
| JP2008534467A5 (enExample) | ||
| JP2017524682A5 (enExample) | ||
| JP2009544318A5 (enExample) | ||
| JP2017515508A5 (enExample) | ||
| Mohammed et al. | Cancer vaccines: past, present, and future | |
| Brenner et al. | Heat shock protein–based therapeutic strategies against human immunodeficiency virus type infection | |
| JP2020528911A5 (enExample) | ||
| JP2020534874A5 (enExample) | ||
| Im et al. | Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding | |
| Wu et al. | DNA vaccine with discontinuous T‐cell epitope insertions into HSP65 scaffold as a potential means to improve immunogenicity of multi‐epitope Mycobacterium tuberculosis vaccine | |
| Memarnejadian et al. | Fusion of HBsAg and prime/boosting augment Th1 and CTL responses to HCV polytope DNA vaccine | |
| JP2016514672A5 (enExample) | ||
| JP2014139185A5 (enExample) |